Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
Ovarian cancer is the second most common gynecological malignancy in resource-rich countries and the third most common in resource-limited countries (after cervical cancer). The majority (95%) of ovarian malignancies originate from epithelial cells, known as epithelial ovarian cancer, which is closely related to fallopian tube cancer and primary peritoneal serous carcinoma. Subtypes of epithelial ovarian cancer include high-grade serous carcinoma, low-grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma, and mucinous carcinoma, with serous carcinoma being the most common (accounting for 75% of epithelial cancers).
The average age of patients is around 60 years, while those with hereditary ovarian cancer syndromes are diagnosed at a younger age. The lifetime risk of developing ovarian cancer is 1.3%. Risk factors include older age, infertility, endometriosis, polycystic ovary syndrome, and smoking (for mucinous carcinoma). About 80% of early-stage patients remain recurrence-free at 5 years. However, most advanced ovarian cancers will eventually relapse, with high mortality rates among recurrent cases.
Ovarian cancer accounts for a high proportion of female malignancies worldwide, with particularly high incidence rates in developed countries such as the United States and parts of Europe. In recent years, incidence has been rising in developing countries, especially in Southeast Asia, such as India and Thailand, due to lifestyle and environmental factors. This growing trend poses a major threat to women’s health.
In the United States, ovarian cancer is the second most common gynecological malignancy and the leading cause of gynecological cancer deaths.
1. High Concealment
Early symptoms of ovarian cancer are not obvious and are often mistaken for digestive system diseases, causing patients to miss the optimal treatment window and increasing the risk of disease progression.
2. High Metastatic Potential
This disease tends to spread through the abdominal cavity and lymphatic system, often presenting with widespread peritoneal dissemination in advanced stages, making treatment difficult and prognosis poor.
3. High Treatment Difficulty
Advanced-stage patients often develop resistance to chemotherapy and have high recurrence rates, leading to immense suffering, life-threatening risks, and significantly reduced quality of life.
Immune reconstruction cell therapy reshapes the patient’s immune system, enabling stronger recognition and attack of cancer cells. The therapy involves reinfusing specific immune cells to help clear residual cancer cells, delay recurrence, and improve tolerance to conventional treatments. This represents an important breakthrough in advancing individualized precision medicine.
In clinical practice, since cancer patients often face impaired immune function, increased infection risks, and slow recovery during surgery, radiotherapy, and chemotherapy, it is essential to scientifically formulate phased immune reconstruction plans across different treatment cycles to better support patients, enhance tolerance, and improve survival quality.
● Short-term Plan: Rapidly enhance immunity through immune cell reinfusion, boosting the effectiveness of anti-cancer treatment.
● Mid-term Plan: Reduce side effects of conventional treatments, promote physical recovery, and complete standardized treatment courses.
● Long-term Plan: Enhance overall immunity through immune cell reconstruction, gut immune reconstruction, elemental immune reconstruction, and immune nutrition reconstruction, thereby improving quality of life and extending survival.
1. Surgical Treatment
Surgery is the primary treatment for ovarian cancer, particularly in early-stage cases. This typically involves removal of the uterus and adnexa, with pelvic and abdominal lymph node dissection if necessary, to maximize tumor removal.
2. Chemotherapy
Chemotherapy is an important method for postoperative adjuvant therapy and for advanced-stage patients. Common drugs include platinum-based and taxane-based agents, which can suppress cancer growth and spread.
3. Radiotherapy
Radiotherapy is mainly used for locally advanced or recurrent cases, in combination with other therapies to control tumors and improve overall treatment outcomes.
4. Targeted Therapy
For patients with BRCA mutations or HRD-positive status, targeted drugs such as PARP inhibitors can significantly prolong progression-free survival. Targeted therapy has relatively fewer side effects, making it more suitable for long-term treatment and recovery.
The hidden nature and high metastatic potential of ovarian cancer make it difficult to treat, requiring emphasis on early diagnosis and comprehensive treatment. Experts at United Life International Medical Center highlight that immune reconstruction cell therapy offers patients new treatment options. Patients are advised to actively cooperate with scientific treatment to improve survival quality.
